Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Health Budget Review Presents Historic Opportunity To Fix Medtech Funding, Says COCIR

Executive Summary

With the EU set to review its long-term budget framework this year, policymakers have a golden opportunity to correct underinvestment in the health sector. Trade body COCIR outlines why and how funding must be allocated to support the medtech industry.

You may also be interested in...



MedTech Forum 2023: Why The Commission Must Not ‘Shoot For The Moon’ With EHDS Plans

EU policymakers have ambitious goals to enable greater sharing of electronic health data through the creation of a European Health Data Space, but experts at the MedTech Forum conference urged the commission to ensure its regulation is implementable.

EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, And When?

The text of the European Commission’s proposed AI Act is expected to enter the EU high-level negotiation stage within weeks, yet many questions remain as to what the final regulation will entail. Lawyers from Cooley LLP tell Medtech Insight why considerable changes to the text are possible, and what the new law is likely to mean for medtech.

MedTech Forum 2023: Europe’s Regulatory Maze Must Be Simplified, But How?

Navigating Europe’s increasingly complex maze of regulations was the topic du jour at this year’s MedTech Forum conference. Despite growing concerns that the EU is losing its historic attractiveness for companies, a spirit of resilience characterized the busy three-day meeting.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel